Facilitated By

San Antonio Medical Foundation

ANBL1531 A PHASE 3 STUDY OF 131I-METAIODOBENZYLGUANIDINE (131I-MIBG) OR CRIZOTINIB ADDED TO INTENSIVE THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED HIGH-RISK NEUROBLASTOMA (NBL) (IND# 134379) (CTMS# 18-0144)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Langevin, Anne-Marie R
Funded by
CHILDREN'S HOSPITAL OF PHILADELPHIA
Research Start Date
Status
Active
Collaborative Project
Clinical Care
Drug Discovery
Cancer